What Does a Phase 1 Clinical Trial Cost?

Why Phase 1 Costs Vary So Much

The cost of a phase 1 clinical trial is shaped by study design, therapeutic area, number of sites, and the type of intervention being tested. A first-in-human oncology study with dose-escalation cohorts costs far more than a healthy-volunteer bioavailability trial, even when both are small. Sponsors who treat phase 1 as a low-budget precursor to pivotal work often underestimate the resources required to run it safely and compliantly.

Typical Cost Ranges by Study Type

Industry benchmarks place the median cost of a single phase 1 trial in the range of roughly $1.4 million to $6.6 million. Within that spread:

• Healthy-volunteer pharmacokinetic or bioequivalence studies often fall in the lower tier, sometimes below $2 million.
• First-in-human oncology trials with multiple dose levels and intensive safety monitoring sit in the middle to upper tier.
• Studies involving complex biologics, gene therapies, or combination products push costs higher because of specialized manufacturing and analytical testing.

Protocol Design Decisions That Move the Budget

Every design choice has a price tag. Escalating the number of dose cohorts adds cohorts of participants, more site visits, and more laboratory draws. Requiring imaging scans or tumor biopsies at each dose level multiplies per-subject costs. Open-label designs are cheaper than randomized, placebo-controlled ones, but the regulatory and ethical expectations around safety monitoring remain the same regardless of blinding.

Site Selection and Geographic Spread

Costs per enrolled participant differ sharply by region. Sites in North America and Western Europe command higher per-visit reimbursement and institutional overhead, while sites in Eastern Europe, Latin America, or parts of Asia can reduce per-patient costs. However, lower site costs do not automatically translate to lower total cost; sponsors must weigh travel, monitoring visits, central labs, and the risk of longer timelines when spreading a trial across many countries.

Endpoints, Assessments, and Hidden Expenses

Phase 1 trials are often justified by safety and pharmacokinetic endpoints, but sponsors frequently add exploratory biomarkers, immune assays, or pharmacodynamic measurements that are not strictly required. These add costs in lab processing, bioanalysis, and statistical programming. Other hidden expenses include:

• Institutional review board or ethics committee fees at each site.
• Centralized imaging or biomarker labs that charge per sample.
• Drug supply manufacturing, packaging, and accountability.
• Data management, eTMF maintenance, and monitoring visits.
• Insurance and indemnity for trial participants.

Timeline and Its Effect on Spend

A phase 1 trial that runs longer than planned because of slow enrollment, dose-limiting toxicities, or regulatory holds accumulates fixed costs for site contracts, monitoring, and drug supply. The cost of a phase 1 clinical trial is therefore not only a function of per-patient spend but also of calendar duration. Sponsors that invest in robust site selection, clear protocols, and realistic feasibility estimates tend to contain both timelines and budgets more effectively.

What Sponsors Can Do to Manage Cost

Several levers help control the cost of a phase 1 clinical trial without compromising safety. Standardizing the protocol across similar programs, using a single central laboratory, limiting the number of exploratory endpoints to those with clear go/no-go value, and selecting sites with proven enrollment speed all reduce waste. Early engagement with regulatory agencies and ethics committees to align on safety monitoring requirements can also prevent costly protocol amendments mid-study.